Hong et al35 used a novel approach to target inflammation and its consequences in patients with advanced cancer. For this purpose, they designed a dose-escalation and expansion approach using a first-in-class monoclonal antibody (MABp1) cloned from a human being that targets IL-1α. The

first, dose-escalation part of the study identified check details an optimal intravenous dose of 3.75 mg/kg every 2 weeks. Using this dose, the following phase II study was performed. In the 42 patients in this open-label, uncontrolled study, median plasma IL-6 concentrations decreased from baseline to week 8 (P = .08). Of the 34 patients who were restaged, 1 patient had a partial response and 10 had stable disease. Among 30 patients with an assessment

of body composition, lean mass increased significantly by 1.02 ± 2.24 kg (P = .02). Overall, the drug was well tolerated. 35 Two recent interventional studies used thalidomide to treat cachexia. Unfortunately, thalidomide is a drug associated IPI-145 cell line with tragedy, because a single dose can induce malformation of the unborn in pregnant women.36 Despite these effects, it has been rediscovered for its anti-inflammatory properties, and reports dating back more than 20 years have demonstrated successful treatment of erythema nodosum leprosum.37 Yennurajalingam et al38 studied 31 patients

with advanced cancer with weight loss of more than 5% in the previous 6 months who also reported anorexia and fatigue. Patients were, in a double-blinded fashion, randomized to receive 100 mg thalidomide daily (n = 15) or placebo for a comparatively short duration of 14 days. Only 21 patients completed the study. Statistically significant decreases were noted for fat mass (median: –1.5 kg, P = .03) and fat-free mass (–4.8 kg, P = .024) after 14 days of treatment with Cobimetinib thalidomide. Some changes with regard to cytokine levels were noted as well; however, no effect was noted for the ESAS, FAACT, the FACIT-F, the Hospital Anxiety Depression Scale, or the Pittsburgh Sleep Quality Index. Another small phase II trial was conducted by Davis et al 39 using 50 mg of thalidomide administered orally at bedtime; however, this trial was uncontrolled and unblinded. Nonresponders with regard to appetite were uptitrated every 2 weeks to 100 mg, then to 200 mg once daily. Of 33 patients with active cancer and loss of appetite as assessed using a numerical rating scale, 64% showed improved appetite. In addition, patients’ insomnia and quality of life categorical scale values increased significantly. Wasting plays a major role not only in patients with cancer, but also in patients with chronic kidney disease.